Segment Information (Schedule of Total Revenues of Top Selling Products) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014 drug		Sep. 30, 2013
Revenue, Major Customer [Line Items]
Revenues	$ 336,117		$ 267,321		$ 920,607		$ 791,186
Number of other insignificant generic drugs					85
Par Pharmaceutical [Member]
Revenue, Major Customer [Line Items]
Revenues	318,784		249,818		871,425		737,733
Par Pharmaceutical [Member] | Budesonide (Entocort EC) [Member]
Revenue, Major Customer [Line Items]
Revenues	32,065		54,952		107,680		150,382
Par Pharmaceutical [Member] | Propafenone Rythmol Sr [Member]
Revenue, Major Customer [Line Items]
Revenues	18,858		19,423		55,235		53,919
Par Pharmaceutical [Member] | Divalproex (Depakote) [Member]
Revenue, Major Customer [Line Items]
Revenues	18,334		0		18,334		0
Par Pharmaceutical [Member] | Omega-3 (Lovaza) [Member]
Revenue, Major Customer [Line Items]
Revenues	17,716		0		17,716		0
Par Pharmaceutical [Member] | Metoprolol Succinate ER (Toprol-XL) [Member]
Revenue, Major Customer [Line Items]
Revenues	16,581		11,450		51,346		31,268
Par Pharmaceutical [Member] | Lamotrigine (Lamictal XR) [Member]
Revenue, Major Customer [Line Items]
Revenues	10,849		26,343		46,765		20,116
Par Pharmaceutical [Member] | Rizatriptan (Maxalt) [Member]
Revenue, Major Customer [Line Items]
Revenues	9,312		12,277		35,525		45,206
Par Pharmaceutical [Member] | Lamotrigine (Lamictal XR) [Member]
Revenue, Major Customer [Line Items]
Revenues	8,789		11,079		29,185		41,725
Par Pharmaceutical [Member] | Rizatriptan (Maxalt) [Member]
Revenue, Major Customer [Line Items]
Revenues	3,760		5,283		7,555		42,296
Par Pharmaceutical [Member] | Par Sterile Products [Member]
Revenue, Major Customer [Line Items]
Revenues	46,751		0		96,479		0
Par Pharmaceutical [Member] | Other [Member]
Revenue, Major Customer [Line Items]
Revenues	126,959	[1]	101,788	[1]	386,369	[1]	330,624	[1]
Par Pharmaceutical [Member] | Other product related royalty streams [Member]
Revenue, Major Customer [Line Items]
Revenues	8,810	[2]	7,223	[2]	19,236	[2]	22,197	[2]
Strativa [Member]
Revenue, Major Customer [Line Items]
Revenues	17,333		17,503		49,182		53,453
Strativa [Member] | Other [Member]
Revenue, Major Customer [Line Items]
Revenues	(1)		(398)		(47)		(877)
Strativa [Member] | Other product related royalty streams [Member]
Revenue, Major Customer [Line Items]
Revenues	1,165	[2]	854	[2]	2,632	[2]	2,725	[2]
Strativa [Member] | Megace ES [Member]
Revenue, Major Customer [Line Items]
Revenues	7,712		9,455		23,644		31,009
Strativa [Member] | Nascobal Nasal Spray [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 8,457		$ 7,592		$ 22,953		$ 20,596

[1] The further detailing of revenues of the other approximately 85 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the nine-month periods ended September 30, 2014 and 2013.

[2] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.